Time Is Brain

Why now? In stroke, every second counts, answers can’t come too late

Despite the progress of Endovascular Thrombectomy (EVT), a highly effective, time-sensitive, minimally invasive procedure to remove large blood clots from brain arteries during an Acute Ischemic Stroke (AIS), stroke care still loses its most valuable asset: time. From the first emergency call or ambulance arrival, patients are moved toward a hospital, but ambulances function like transport buses: no neurological capability, no real‑time brain data. Critical minutes pass while the brain remains unmonitored, imaging isn’t yet available, and teams can’t confirm treatment eligibility, driving irreversible damage and poorer outcomes.

BraiN20® changes the equation. It is the only real‑time, continuous brain‑viability monitor that travels with the patient across the entire pathway (from ambulance to ER, angio‑suite and ICU) turning the diagnostic delay window into actionable, objective information.

Redefining the “Patient Journey”: From reactive diagnosis to precision intervention

BraiN20® is not just a device; it is the new standard transforming every critical stage of the stroke patient pathway:

• Objective triage in the Ambulance & ER: Currently, triage relies on subjective clinical scales. BraiN20® enables an objective diagnosis in just 33 seconds, immediately identifying candidates for endovascular treatment (EVT). This accelerates direct transfer to the appropriate center, avoiding vital time loss and allowing for continuous monitoring during transit. Furthermore, BraiN20® is so intuitive that any technician can operate it without the need for complex training.
• Live functional guidance during EVT: For the first time, interventional neurologists have a “real-time functional map” during thrombus extraction. BraiN20® immediately detects whether reperfusion is effective or if complications arise, increasing the procedure’s success rate by 26%.
• Continuous bedside surveillance post‑procedure: Monitoring does not end in the operating room. BraiN20® provides bedside surveillance to detect re-occlusions or early deterioration long before symptoms become visible, enabling an immediate medical response and protecting the salvaged brain tissue.

Bottom line: We move from passive waiting to real-time visibility. From minute one, we see exactly what the brain needs. This is the inflection point to transform outcomes, slash system costs, and set the new global standard of care.

BraiN20®: The “ECG for Stroke” for continuous brain monitoring

Our patented technology provides instant access to brain health through:

• N20 Signal Recording: A clinically validated biomarker based on a brain signal that reflects the functional status of broad cortical regions. The N20 originates from the brain’s Somatosensory Evoked Potentials (SEP) — electrical responses generated when the median nerve is stimulated. As the earliest cortical arrival of that signal, its presence and quality serve as a robust marker of cortical viability in acute neurological conditions, as demonstrated in the PROMISE clinical study (for more information please refer to “The project” section).
• Outcome‑Prediction AI: Proprietary software that predicts patient prognosis with 93% sensitivity before treatment and 100% during EVT, outperforming conventional imaging when time matters most.
• Portable, non‑invasive hardware: Single‑use stimulation and recording components designed for any setting: ambulance, ER, angio‑suite, or ICU.

Key advantages & market potential

• Clinical efficiency: Cuts time‑to‑treatment by up to 140 minutes and optimises patient flow, routing candidates directly to EVT‑capable centers from the ambulance.
• Economic impact: Targets a massive human and economic burden; stroke‑related disability drives €891B in global annual costs.
• Tier‑1 validation: Supported by the PROMISE clinical study (223 patients), backed by 40+ KOLs and 13 hospitals.
• Strong IP: A robust patent portfolio protected through 2040.

World‑class team & executable plan

Time is Brain is a spin‑off of Germans Trias Hospital, pioneer and architect of Spain’s national Stroke Code. The company is led by stroke‑specialist neurologists Alicia Martínez, MD, PhD Jaume Coll, MD, PhD and global KOL Antonio Dávalos, MD, PhD, combining frontline clinical leadership with seasoned MedTech business execution.

With CE mark and U.S. market entry (FDA) expected during 2026, Time is Brain is positioned to transform global neurovascular care and generate significant returns through a strategic M&A pathway.

Since inception, the company has raised €1.8M in equity and €4.2M in non‑dilutive public funding, including the EIC Accelerator. Time is Brain is currently opening a €2.5M round, with ~2M€ already committed, to:

1. Complete the FDA dossier,
2. Execute the EU commercial launch, and
3. Prepare U.S. market entry